FDA
-
-
-
-
-
-
-
EMA accepts Teva application for long-acting olanzapine schizophrenia drug
-
-
-
-
-
-
-
FDA accepts Teva's drug application for monthly schizophrenia treatment
-
-
-
-
-
-
-
Teva's AJOVY reduces migraine days in children in clinical trial
-
-
-
-
-
-
-
Teva submits FDA application for monthly schizophrenia injection
-
-
-
-
-
-
-
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
-
-
-
-
-
-
-
Teva Pharma (TEVA) Announces FDA Filing Acceptance for AJOVY in Pediatric Episodic Migraine Prevention
-
-
-
-
-
-
-
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (o
-
325,445 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

